Skip to main content
search

Parliamentary Debates and Questions

S5W-16223: Miles Briggs (Lothian)

Scottish Conservative and Unionist Party

Date lodged: 26 April 2018

To ask the Scottish Government which drugs are available through the NHS in England but not in Scotland, and vice-versa.

Answered by: Shona Robison 10 May 2018

Medicines that have been approved for use in Scotland and not England:

Bevacizumab (Avastin)Regorafenib (Strivarga)Nusinersen (Spinraza)

The Scottish Medicines Consortium published advice on 7 th May 2018 which accepted both Regorafenib (Strivarga) and Nusinersen (Spinraza) for use by the NHS in Scotland.

The first three medicines are used to treat certain indications in ovarian, breast and liver cancer respectively. Nusinersen (Spinraza) has been accepted for restricted use in type 1 spinal muscular atrophy.

Medicines that have been approved for use in England and not Scotland:

Cabozantinib (Cometriq)Pertuzumab (Perjeta)Atezolizumab (Tecentriq)Obinutuzumab (Gazyvaro)Eculizumab (Soliris)Etelcalcetide (Parsabiv)

The first five medicines are used to treat certain indications in thyroid, skin, breast, bladder and lymphatic cancers respectively. The remaining medicines are used in the treatment of kidney disease, a rare metabolic disorder and Duchenne muscular dystrophy respectively.

In the case of Perjeta, my officials most recently met with the manufacturer, Roche, on 4 May. Roche has also held discussions with NHS NSS National Procurement and I expect that dialogue to continue in order that Roche can bring forward a new submission to the Scottish Medicines Consortium for their consideration.